Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) traded at $4.22 at last check on Friday, Nov 20, making an upward move of 3.43% on its previous day’s price.
Looking at the stock we see that its previous close was $4.08 and the beta (5Y monthly) reads 2.94 with the day’s price range being $4.0800 – 4.3195. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, ZYNE has a high of $7.45 and a low of $2.55. The company’s stock has gained about 16.25% over that past 30 days.
Zynerba has a market cap of $122.59 Million and is expected to release its quarterly earnings report on November 09, 2020. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the ZYNE stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.35, with the EPS growth for the year declined at -$1.93 for 2020 and -$1.43 for next year. These figures represent 0.29% and at -0.26% growth in EPS for the two years respectively.
There have been 2 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the ZYNE stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 50% Buy.
Let’s briefly compare Zynerba (ZYNE) stock to its peers. We find that today’s price change of +3.43% and -37.3% over the past 12 months for ZYNE competes that of Dr. Reddy’s Laboratories Ltd (RDY), which has seen its stock price fall -0.03% in the latest trading session and is +56.38% over the last one year. Another of its peers Teva Pharmaceutical Industries Ltd (TEVA) has climbed 1.39% today, but is -7.51% down over the past year, while Mylan NV Ord Shs (MYL) is also up 3.43% yet its price remains in the red at -37.3% over the same period. Dr. has a P/E ratio of 41.9 compared to Zynerba’s 0 and Teva’s 0. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -0.68% and -0.75%, respectively, in early deals.
Coming back to Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), we note that the average 3-month trading volume was 537.6 Million, while that of the preceding 10-day period stands at 665.29 Million. Current shares outstanding are 29.44 Million.
According to data from Thomson Reuters, insiders hold 7.11% of the company’s shares while institutions hold 22.04%. The data shows that short shares as of October 29, 2020, stood at 4.37 Million at a short ratio of 8.67. This represents a 14.83% Short interest in Shares outstanding on October 29, 2020. Shares short dropped in October from the previous month at 4.38 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -30.13% down in year-to-date price movement.